MHRA (UK) approves first-in-class Truqap (capivasertib), in combination with fulvestrant, for treating the most common type of advanced breast cancer.-AstraZeneca
The Medicines & Healthcare products Regulatory Agency (MHRA) has approved a first-in-class drug, capivasertib (Truqap), in combination with fulvestrant, for treating the most common type of advanced breast cancer
The drug will be available to people in the UK with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER-2) negative breast cancer, with one or more PIK3CA, AKT1 or PTEN-alterations following recurrence or progression on or after an endocrine based regimen. Tumours with mutations or alterations in the PIK3CA, AKT1 or PTEN genes are found in approximately half of patients with this form of breast cancer.
Capivasertib works in a new way, by blocking the activity of the cancer driving protein molecule, AKT. Capivasertib was discovered by AstraZeneca, subsequent to a collaboration with Astex Pharmaceuticals, and its collaboration with The Institute of Cancer Research (ICR) and Cancer Research Technology Limited.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
2 mins